Related Experiment Video
Updated: Feb 7, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience
Introduction:
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by Ga/Lu-DOTATATE could evolve as a novel theranostic option.
Methods:
Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using Ga-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with Lu-DOTATATE. Response to therapy was assessed by thyroglobulin (Tg) and morphological and metabolic criteria based on interim and follow-up Ga-DOTATATE-PET/CTs. Analysis was performed on a per-patient basis.
Results:
In the post-therapy evaluation, only one out of five patients showed a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels.
Conclusion:
In this case study of five patients, Lu-DOTATATE therapy showed only heterogeneous response and efficacy in RrDTC patients despite good lesional uptake in pre-therapeutic PET.
Insights
Radioiodine-refractory differentiated thyroid cancer (RrDTC) patients receiving Lutetium-DOTATATE (Lu-DOTATATE) showed limited efficacy. Despite somatostatin receptor expression, only one of five patients responded, indicating heterogeneous outcomes for this novel theranostic option.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- Radioiodine-refractory differentiated thyroid cancer (RrDTC) presents a poor prognosis.
- Novel therapeutic strategies are crucial for RrDTC management.
- Somatostatin receptor (SSRT) expression in some RrDTCs offers a potential therapeutic target.
Purpose of the Study:
- To evaluate the efficacy of Lutetium-DOTATATE (Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT) in RrDTC patients.
- To assess the theranostic potential of targeting SSRTs in RrDTC.
Main Methods:
- Five RrDTC patients with SSRT expression (confirmed by Ga-DOTATATE-PET/CT) received 2-4 cycles of Lu-DOTATATE PRRT.
- Treatment response was evaluated using thyroglobulin levels and imaging (Ga-DOTATATE-PET/CT) criteria.
- Per-patient analysis was conducted to assess outcomes.
Main Results:
- One out of five patients achieved a partial response.
- Three patients experienced progressive disease.
- One patient showed stable imaging but rising thyroglobulin levels, indicating discordant response.
Conclusions:
- Lu-DOTATATE PRRT demonstrated heterogeneous response and limited efficacy in this cohort of RrDTC patients.
- Despite pre-therapeutic SSRT expression and uptake, clinical benefit was inconsistent.
- Further research is needed to optimize theranostic approaches for RrDTC.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...

